Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||||||||
Assets Current | |||||||||||||||||
Cash And Cash Equivalents At Carrying Value | 42 | 48 | 53 | 60 | 65 | 73 | 79 | 86 | 84 | 77 | 83 | 91 | |||||
Prepaid Expense And Other Assets Current | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 3 | 4 | |||||
Assets Current | 43 | 49 | 54 | 61 | 66 | 75 | 80 | 87 | 85 | 78 | 86 | 96 | |||||
Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | |||||
Restricted Cash Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Operating Lease Right Of Use Asset | 2 | 2 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | |||||
Finance Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Assets | 45 | 52 | 56 | 63 | 69 | 77 | 82 | 90 | 88 | 81 | 89 | 99 | |||||
Liabilities And Stockhold… | |||||||||||||||||
Liabilities Current | |||||||||||||||||
Notes Payable Current | - | - | - | - | - | - | - | - | 8 | 8 | 8 | 9 | |||||
Accounts Payable And Accrued Liabilities Current | 7 | 7 | 6 | 8 | 7 | 8 | 7 | 9 | - | 8 | - | - | |||||
Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Finance Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Liabilities Current | 7 | 8 | 7 | 8 | 7 | 8 | 8 | 10 | 8 | 8 | 9 | 9 | |||||
Deferred Revenue | - | - | - | - | - | - | - | - | - | - | - | 35 | |||||
Deferred Revenue Noncurrent | - | - | - | - | - | - | - | - | 35 | 35 | 35 | - | |||||
Contract With Customer Liability Noncurrent | 35 | 35 | 35 | 35 | 35 | 35 | 35 | 35 | - | 35 | - | - | |||||
Operating Lease Liability Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | - | |||||
Finance Lease Liability Noncurrent | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | |||||
Liabilities | 43 | 44 | 42 | 44 | 43 | 44 | 44 | 46 | 44 | 45 | 45 | 46 | |||||
Stockholders Equity | |||||||||||||||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Additional Paid In Capital | 418 | 418 | 418 | 418 | 417 | 409 | 407 | 401 | 390 | 374 | 372 | 368 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | -0 | -0 | - | - | - | - | - | - | - | - | - | - | |||||
Retained Earnings Accumulated Deficit | -415 | -410 | -404 | -399 | -392 | -376 | -369 | -358 | -346 | -338 | -328 | -315 | |||||
Stockholders Equity | 2 | 8 | 14 | 19 | 26 | 33 | 38 | 44 | 44 | 36 | 44 | 53 | |||||
Liabilities And Stockholders Equity | 45 | 52 | 56 | 63 | 69 | 77 | 82 | 90 | 88 | 81 | 89 | 99 | |||||
Accumulated Depreciation Depletion And Amortizatio… | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Preferred Stock Par Or Stated Value Per Share | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | |||||
Preferred Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||
Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Par Or Stated Value Per Share | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | |||||
Common Stock Shares Authorized | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | |||||
Common Stock Shares Issued | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 29 | 28 | 27 | 27 | |||||
Shares Outstanding | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 29 | 28 | 27 | 27 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -3.82% | -24.43% | -31.98% | - | - | - | - | - | - | - | - | - |
| 2025 | 4.05% | -4.05% | 20.95% | 15.58% | 4.55% | 8.44% | 12.60% | 7.87% | -8.66% | 29.29% | 19.19% | 4.04% |
| 2024 | 42.65% | 13.83% | 8.44% | -19.76% | -27.42% | -32.26% | -17.58% | -12.73% | -29.70% | -18.63% | 1.86% | -6.83% |
| 2023 | -7.38% | -19.35% | -24.05% | 3.16% | -4.11% | -24.80% | -2.62% | 15.94% | 9.61% | - | - | - |
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Metrics | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liquidity Ratios | |||||||||||||||||
| Current Ratio | 5.89 | 6.20 | 7.96 | 7.34 | 9.35 | 9.14 | 10.25 | 8.95 | 10.59 | 9.21 | 9.87 | 10.44 | |||||
| Quick Ratio | 5.73 | 6.02 | 7.81 | 7.21 | 9.19 | 8.95 | 10.14 | 8.84 | 10.42 | 9.03 | 9.57 | 9.97 | |||||
| Working Capital | 35.91M | 41.41M | 47.53M | 52.72M | 59.35M | 66.36M | 71.77M | 77.34M | 77.31M | 69.77M | 76.92M | 86.39M | |||||
Leverage & Debt | |||||||||||||||||
| Debt to Equity | 18.72 | 5.61 | 3.07 | 2.31 | 1.67 | 1.35 | 1.15 | 1.05 | 1.01 | 1.24 | 1.04 | 0.87 | |||||
| Interest Coverage TTM | - | - | - | - | - | -45.44 | -23.10 | -15.46 | -14.34 | -16.74 | -19.39 | -24.44 | |||||
| Debt Ratio | 0.95 | 0.85 | 0.75 | 0.70 | 0.63 | 0.57 | 0.53 | 0.51 | 0.50 | 0.55 | 0.51 | 0.46 | |||||
Efficiency & Turnover | |||||||||||||||||
| Asset Turnover TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Per Share Metrics | |||||||||||||||||
| Diluted EPS TTM | -0.25 | -0.36 | -0.37 | -0.44 | -0.49 | -0.42 | -0.44 | -0.47 | -0.56 | -0.61 | -0.62 | -0.59 | |||||
| Free Cash Flow Per Share TTM | -0.73 | -0.79 | -0.80 | -0.98 | -1.07 | -1.10 | -1.12 | -1.13 | -1.42 | -1.78 | -1.77 | -1.62 | |||||
| Dividend Per Share TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Margin Metrics | |||||||||||||||||
| Operating Profit Margin TTM | -28,346.67% | -40,274.44% | -41,486.67% | - | - | - | - | - | - | - | - | -107,368.89% | |||||
| Net Profit Margin TTM | -26,078.89% | -37,652.22% | -38,443.33% | - | - | - | - | - | - | - | - | -102,975.56% | |||||
Growth Metrics | |||||||||||||||||
| Net Revenue Growth (1Y) | - | - | - | - | - | - | - | -100.00% | -100.00% | -100.00% | -100.00% | -96.37% | |||||
| Net Income Growth (1Y) | -48.43% | -11.39% | -15.44% | -3.72% | -2.02% | -21.66% | -18.40% | -8.02% | 19.33% | 47.86% | 65.05% | 69.56% | |||||
| EPS Growth (1Y) | -48.50% | -14.59% | -15.77% | -7.10% | -12.42% | -30.69% | -28.94% | -19.89% | 9.96% | 34.17% | 53.49% | 53.48% | |||||
Valuation Metrics | |||||||||||||||||
| P/E TTM | -1.32 | -1.25 | -1.44 | -1.06 | -1.10 | -0.99 | -1.43 | -5.23 | -4.70 | -2.77 | -3.19 | -4.20 | |||||
| P/B TTM | 13.49 | 5.42 | 3.62 | 2.30 | 1.95 | 1.16 | 1.53 | 5.08 | 4.98 | 3.72 | 3.68 | 3.67 | |||||
| P/S TTM | 345.35 | 471.40 | 554.59 | - | - | - | - | - | - | - | - | 4,323.04 | |||||
| Market Cap | 31.08M | 42.43M | 49.91M | 43.67M | 50.23M | 37.89M | 58.41M | 222.76M | 218.35M | 135.15M | 160.19M | 194.54M | |||||
| Enterprise Value | -11.38M | -5.90M | -3.80M | -16.57M | -15.41M | -35.32M | -20.54M | 136.43M | 141.52M | 66.14M | 85.05M | 111.59M | |||||
Calculated Values | |||||||||||||||||
| Free Cash Flow TTM | -22.88M | -24.58M | -25.04M | -30.69M | -33.27M | -33.08M | -34.82M | -34.00M | -39.72M | -47.49M | -47.79M | -42.43M | |||||
| Net Debt | -42.46M | -48.32M | -53.71M | -60.24M | -65.63M | -73.21M | -78.96M | -86.33M | -76.83M | -69.01M | -75.14M | -82.94M | |||||
Per-Share and Margin | |||||||||||||||||
| EPS TTM | |||||||||||||||||
| Adjusted EPS TTM | |||||||||||||||||
| Cash Flow Per Share TTM | |||||||||||||||||
| Pretax Margin TTM | |||||||||||||||||
| Stock Comp to Revenue TTM | |||||||||||||||||
Turnover Ratios and Averages | |||||||||||||||||
| Average Assets | |||||||||||||||||
| Average Equity | |||||||||||||||||
| Average Inventory | |||||||||||||||||
| Average Receivables | |||||||||||||||||
| Average Accounts Payables | |||||||||||||||||
| Inventory Turnover TTM | |||||||||||||||||
| Payables Turnover TTM | |||||||||||||||||
| Days Inventory Outstanding TTM | |||||||||||||||||
| Days Payables Outstanding TTM | |||||||||||||||||
| Cash Conversion Cycle TTM | |||||||||||||||||
| Working Capital to Revenue | |||||||||||||||||
| Deferred Revenue to Revenue | |||||||||||||||||
Growth Rates | |||||||||||||||||
| Total Assets Growth (1Y) | |||||||||||||||||
| Total Assets Growth (3Y) | |||||||||||||||||
| Total Assets Growth (5Y) | |||||||||||||||||
| Dividends Paid Growth (1Y) | |||||||||||||||||
| Dividends Paid Growth (3Y) | |||||||||||||||||
| Dividends Paid Growth (5Y) | |||||||||||||||||
| EPS Growth (3Y) | |||||||||||||||||
| EPS Growth (5Y) | |||||||||||||||||
| Net Income Growth (3Y) | |||||||||||||||||
| Net Income Growth (5Y) | |||||||||||||||||
| Net Profit Margin Growth (1Y) | |||||||||||||||||
| Net Profit Margin Growth (3Y) | |||||||||||||||||
| Net Profit Margin Growth (5Y) | |||||||||||||||||
| Net Revenue Growth (3Y) | |||||||||||||||||
| Net Revenue Growth (5Y) | |||||||||||||||||
| Deferred Revenue Growth (1Y) | |||||||||||||||||
| Retained Earnings Growth (1Y) | |||||||||||||||||
Credit, Liquidity, Returns, Payout | |||||||||||||||||
| Cash Ratio | |||||||||||||||||
| Net Working Capital | |||||||||||||||||
| Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to Equity | |||||||||||||||||
| Altman A | |||||||||||||||||
| Altman B | |||||||||||||||||
| Altman C | |||||||||||||||||
| Altman D | |||||||||||||||||
| Altman E | |||||||||||||||||
| Altman Z-Score | |||||||||||||||||
| ROA TTM | |||||||||||||||||
| ROE TTM | |||||||||||||||||
| NOPAT TTM | |||||||||||||||||
| ROIC TTM | |||||||||||||||||
| Effective Tax Rate TTM | |||||||||||||||||
| Payout Ratio TTM | |||||||||||||||||
| Dilution Ratio | |||||||||||||||||
| Retained Earnings to Equity | |||||||||||||||||
| Treasury Stock to Equity | |||||||||||||||||
| Treasury Stock Change (1Y) | |||||||||||||||||
| Accrued to Current Liabilities | |||||||||||||||||
Valuation Ratios | |||||||||||||||||
| P/CF TTM | |||||||||||||||||
| Dividend Yield TTM | |||||||||||||||||
| Free Cash Flow Yield TTM | |||||||||||||||||
| EV EBITDA TTM | |||||||||||||||||
| EV EBIT TTM | |||||||||||||||||
| Stock Compensation TTM | |||||||||||||||||
| Adjusted Net Income TTM | |||||||||||||||||
| Billings TTM | |||||||||||||||||
| Total Debt | |||||||||||||||||
| Invested Capital | |||||||||||||||||
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Actinium Pharmaceuticals, Inc. (ATNM) — SEC Financial Statements & Analysis
Actinium Pharmaceuticals, Inc. (ATNM) is a pharmaceutical preparations company, incorporated in DE. Actinium Pharmaceuticals, Inc. trades on NYSE as: ATNM. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Actinium Pharmaceuticals, Inc. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 18.72x, a Price-to-Sales (P/S) ratio of 345.35x (TTM), a Price-to-Book (P/B) ratio of 13.49 (TTM), at a market cap of $31.08M. Figures below are sourced from SEC EDGAR, as-filed.
- Net Revenue TTM Growth 1Y
- -100.00%
- Debt To Equity
- 18.72x
- P/S TTM
- 345.35x
- P/B TTM
- 13.49
- Market Cap
- $31.08M
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Actinium Pharmaceuticals, Inc. in?
Actinium Pharmaceuticals, Inc. (ATNM) operates in the Pharmaceutical Preparations industry.
What is ATNM's market cap?
Actinium Pharmaceuticals, Inc. (ATNM) has a market capitalization of $31.08M as of 2026-03-31.
What exchange does ATNM trade on?
Actinium Pharmaceuticals, Inc. (ATNM) trades on the NYSE.
Where is Actinium Pharmaceuticals, Inc. incorporated?
Actinium Pharmaceuticals, Inc. is incorporated in DE.